Immune drug shows promise against rare HPV throat tumors
NCT ID NCT02632344
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug pembrolizumab in 21 people with recurrent respiratory papillomatosis (RRP), a rare condition where HPV causes non-cancerous growths in the throat, windpipe, or lungs. The goal was to see if the drug could shrink these growths and reduce the need for frequent surgeries. Researchers measured response using endoscopic scores and standard tumor criteria, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT RESPIRATORY PAPILLOMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NorthShore University HealthSystem
Evanston, Illinois, 60208, United States